COMT Inhibition Among Individuals With Comorbid AUD/ADHD
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT)
inhibitor tolcapone, relative to placebo, affects response to alcohol, decision-making, brain
activation associated with alcohol cue reactivity, response inhibition, and selective
attention, or alcohol drinking.
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of South Carolina University of Colorado, Denver
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)